{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:52Z","timestamp":1786119712789,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    Peptide receptor radionuclide therapy has revolutionized the management of somatostatin receptor-positive metastatic neuroendocrine tumours. Treating nuclear medicine physicians must be aware of the radiation hazards posed by radioactive contamination and the imaging fallacies attributable to radioactive contamination on posttherapy planar imaging. The image fallacies, if not properly looked upon, upstage the disease. Also, radioactive contamination with body fluids on any external structure in close contact with the patients poses a prolonged radiation hazard. The authors in this present research demonstrate image fallacy due to radioactive urinary contamination on\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE posttherapy imaging.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005990","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:00:59Z","timestamp":1747738859000},"page":"e142-e143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Circlet Sign"],"prefix":"10.1097","volume":"51","author":[{"given":"Srinivas Ananth","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu Kumar","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhur Kumar","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/biomedicines11041024","article-title":"Efficacy and safety of [177Lu]Lu-DOTA-TATE in adults with inoperable or metastatic somatostatin receptor-positive pheochromocytomas\/paragangliomas, bronchial and unknown origin neuroendocrine tumors, and medullary thyroid carcinoma: a systematic literature review","volume":"11","author":"Hertelendi","year":"2023","journal-title":"Biomedicines"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12149-018-1230-7","article-title":"Manual on the proper use of lutetium-177-labeled somatostatin analogue (Lu-177-DOTA-TATE) injectable in radionuclide therapy (2nd ed.)","volume":"32","author":"Hosono","year":"2018","journal-title":"Ann Nucl Med"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"e13464","DOI":"10.1111\/jne.13464","article-title":"Toxicity manifestations encountered in peptide receptor radionuclide therapy setting","volume":"37","author":"Parghane","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40658-019-0243-1","article-title":"Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"6","author":"Levart","year":"2019","journal-title":"EJNMMI Phys"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2214\/AJR.19.21123","article-title":"Therapy with 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors","volume":"213","author":"Kendi","year":"2019","journal-title":"AJR Am J Roentgenol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:00:20Z","timestamp":1786042820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005990"}},"subtitle":["Urinary Contamination on 177Lu-DOTATATE Posttherapy Imaging"],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005990","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"2025-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}